


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the above-identified application.

Listing of Claims

Claims 1-20 are cancelled.

21 (**Currently Amended**). A compound which is 8-chloro-3-pentyl-3,7-dihydro-1*H*-purine- 2,6-dione:



a pharmaceutically acceptable salt thereof.

22 (**Currently Amended**). A compound ~~according to claim 21, where the compound which~~ is 8-chloro-3-pentyl-3,7-dihydro-1*H*-purine- 2,6-dione.

23 (**Previously presented**). A pharmaceutical formulation, which comprises a compound according to claim 21, and one or more physiologically acceptable diluents, excipients or carriers.

24 (**Cancelled**).

25 (**Cancelled**).

26 (**Currently Amended**). A method for treatment of coronary artery disease ~~or atherosclerosis~~, which comprises administering a therapeutically effective amount of a compound of claim 21 to a human subject in need thereof.

27 (New). A pharmaceutical formulation, which comprises a compound according to claim 22, and one or more physiologically acceptable diluents, excipients or carriers.

28 (New). A method for treatment of atherosclerosis, which comprises administering a therapeutically effective amount of a compound of claim 21 to a human subject in need thereof.

29 (New). A method for treatment of mixed dyslipidaemia, which comprises administering a therapeutically effective amount of a compound of claim 21 to a human subject in need thereof.

30 (New). A method for treatment of diabetic dyslipidaemia, which comprises administering a therapeutically effective amount of a compound of claim 21 to a human subject in need thereof.

31 (New). A method for treatment of hyperlipidaemia, which comprises administering a therapeutically effective amount of a compound of claim 21 to a human subject in need thereof.

32 (New). A method for treatment of hyperlipoproteinaemia, which comprises administering a therapeutically effective amount of a compound of claim 21 to a human subject in need thereof.

33 (New). A method for treatment of hypercholesterolaemia, which comprises administering a therapeutically effective amount of a compound of claim 21 to a human subject in need thereof.

34 (New). A method for treatment of hypertriglyceridaemia, which comprises administering a therapeutically effective amount of a compound of claim 21 to a human subject in need thereof.

35 **(New)**. A method for treatment of coronary artery disease, which comprises administering a therapeutically effective amount of a compound of claim 22 to a human subject in need thereof.

36 **(New)**. A method for treatment of atherosclerosis, which comprises administering a therapeutically effective amount of a compound of claim 22 to a human subject in need thereof.

37 **(New)**. A method for treatment of mixed dyslipidaemia, which comprises administering a therapeutically effective amount of a compound of claim 22 to a human subject in need thereof.

38 **(New)**. A method for treatment of diabetic dyslipidaemia, which comprises administering a therapeutically effective amount of a compound of claim 22 to a human subject in need thereof.

39 **(New)**. A method for treatment of hyperlipidaemia, which comprises administering a therapeutically effective amount of a compound of claim 22 to a human subject in need thereof.

40 **(New)**. A method for treatment of hyperlipoproteinaemia, which comprises administering a therapeutically effective amount of a compound of claim 22 to a human subject in need thereof.

41 **(New)**. A method for treatment of hypercholesterolaemia, which comprises administering a therapeutically effective amount of a compound of claim 22 to a human subject in need thereof.

42 **(New)**. A method for treatment of hypertriglyceridaemia, which comprises administering a therapeutically effective amount of a compound of claim 22 to a human subject in need thereof.